Drugs / SCRI-CAR22v2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04571138 | Sep 2020 → Aug 2025 overdue | leukemia, lymphoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-CAR22v2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04571138 ↗ |
| Modality | Cell therapy | “T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR)” NCT04571138 ↗ |
| Target | CD22 | “The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells.” NCT04571138 ↗ |